Epigenome Editing for Age-Related Dysfunction

What Epigenome Editing Means

The epigenome includes chemical and structural features that help regulate how genomic information is used, including DNA methylation and histone modifications. In a common editing design, a guide RNA directs nuclease-inactive Cas9 (dCas9) to a chosen sequence, while an attached effector writes, removes, or interprets a regulatory mark. Examples include DNMT3A-derived effectors for DNA methylation and TET1-derived effectors for DNA demethylation. [3] [4]

This differs from conventional genome editing because dCas9 is used as a programmable binding platform rather than to create a targeted DNA break. It also differs from partial cellular reprogramming, which exposes cells to broad transcription-factor programs; epigenome editing instead aims to alter selected loci or regulatory programs. Some systems can establish transcriptional memory that persists after the editor is removed, although persistence depends on the target, cell state, and effector design. [5] [11]

Why Age-Related Targets Are Difficult to Define

Epigenetic alteration is one recognized feature of ageing biology, but it encompasses many processes rather than one uniform programme. Human studies identify both shared and tissue-specific changes in DNA methylation with age, and the relationship between a methylation difference and gene expression is not consistent across all loci. [1] [2]

Epigenetic clocks use combinations of age-associated methylation sites as predictors. A site can be informative for prediction without being a driver of cellular dysfunction. Editing a clock-associated CpG may therefore change a measured age signal without repairing the processes that produced it. The causal status of many age-associated modifications remains unresolved. [6]

Editing Strategies Under Study

What the Evidence Shows

A direct ageing-focused experiment edited individual age-associated CpGs and multiplexed sets of age-related regions in human T cells and mesenchymal stromal cells. The edits produced reproducible methylation changes at other age-associated sites, suggesting that some clock-associated regions participate in wider regulatory networks. The study was conducted in cultured cells and did not demonstrate restored tissue function, reduced disease, or longer lifespan. [6]

A separate study edited methylation at the CDKN2B (p15) promoter in human haematopoietic stem and progenitor cells. The induced methylation persisted during differentiation and after engraftment in mice, reduced p15 expression, and changed proportions of some blood-cell populations. This provides evidence that a targeted methylation state can influence cell behaviour, but the experiment modelled an abnormal state associated with myeloid disease rather than reversing normal haematopoietic ageing. [7]

In-vivo platform studies are further advanced for discrete disease-related targets. An mRNA editor delivered by lipid nanoparticles produced durable methylation and silencing of PCSK9 in transgenic mice and lowered circulating PCSK9 and LDL cholesterol in cynomolgus monkeys. A compact AAV-delivered repressor has also reduced Apoe expression in the mouse hippocampus. These studies demonstrate delivery and target engagement in living animals; they do not establish treatment of ageing as a systemic process or show clinical benefit in older humans. [9] [10]

Delivery, Durability, and Safety

Epigenome editors combine a DNA-targeting protein, one or more guides, and an effector, making delivery a substantial engineering constraint. AAV vectors can support tissue-directed expression but have limited payload capacity and may require split or compact systems. Lipid nanoparticles can deliver editor mRNA transiently, but current biodistribution is strongly formulation- and tissue-dependent. [9] [10] [11]

A durable edit could reduce the need for repeated dosing, but the same persistence increases the consequence of choosing the wrong target or changing expression too strongly. Complementary activators have reversed targeted PCSK9 silencing in mice, yet reversibility has not been established for every editor, locus, tissue, or timescale. [5] [9]

Safety assessment must extend beyond unintended DNA-sequence changes. Relevant outcomes include off-target methylation, local spreading around the intended site, altered expression of nearby or networked genes, immune responses to delivery components, and different effects across cell types. Studies using dCas9 methyltransferases have reported both off-target differentially methylated regions and broader bystander effects, showing why guide-sequence prediction alone is insufficient. [6] [8] [11]

Evidence Quality and Interpretation

Confidence is high that programmable epigenetic editors can alter selected regulatory states and change expression at some loci in cells. There is also preclinical evidence that selected edits can persist in differentiated cells and living animals. [5] [7] [9]

Confidence is much lower that editing age-correlated marks will correct age-related dysfunction. The field has not yet established which methylation or chromatin changes are causes, compensations, or measurements of ageing, and direct functional evidence remains limited. A change in an epigenetic clock should therefore be treated as a molecular endpoint rather than proof of tissue rejuvenation. [2] [6]

Summary

Epigenome editing offers a way to test whether particular regulatory changes contribute to age-associated cell dysfunction and, potentially, to modify well-defined disease pathways without intentionally rewriting DNA sequence. Current research establishes molecular control and some durable effects in preclinical systems, but it does not establish a general therapy for human ageing. Progress depends as much on causal target selection and tissue-specific delivery as on the editing machinery itself. [6] [9] [11]

References

1. López-Otín, C. et al. "Hallmarks of Aging: An Expanding Universe." Cell (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC10809922/
2. Day, K. et al. "Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape." Genome Biology (2013). https://doi.org/10.1186/gb-2013-14-9-r102
3. Vojta, A. et al. "Repurposing the CRISPR-Cas9 system for targeted DNA methylation." Nucleic Acids Research (2016). https://doi.org/10.1093/nar/gkw159
4. Xu, X. et al. "A CRISPR-based approach for targeted DNA demethylation." Cell Discovery (2016). https://doi.org/10.1038/celldisc.2016.9
5. Nuñez, J. K. et al. "Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing." Cell (2021). https://doi.org/10.1016/j.cell.2021.03.025
6. Liesenfelder, S. et al. "Epigenetic editing at individual age-associated CpGs affects the genome-wide epigenetic aging landscape." Nature Aging (2025). https://doi.org/10.1038/s43587-025-00841-1
7. Saunderson, E. A. et al. "CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny." Proceedings of the National Academy of Sciences (2023). https://doi.org/10.1073/pnas.2300224120
8. Lin, L. et al. "Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases." GigaScience (2018). https://doi.org/10.1093/gigascience/giy011
9. Tremblay, F. et al. "A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels." Nature Medicine (2025). https://doi.org/10.1038/s41591-025-03508-x
10. Kantor, B. et al. "The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders." Nature Communications (2024). https://doi.org/10.1038/s41467-024-50515-6
11. Ueda, J., Yamazaki, T. & Funakoshi, H. "Toward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges." International Journal of Molecular Sciences (2023). https://doi.org/10.3390/ijms24054778